You can find the annual or quarterly income statement of Apimeds Pharmaceuticals US Inc here for insights into the performance and operational efficiency of Apimeds Pharmaceuticals US Inc.

Quarterly

Quarterly+Annual

Quarterly

Annual

YOY

Hide blank rows

FY2025Q3

FY2025Q2

FY2025Q1

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022Q4

Operating expenses

514.75%1.84M

522.76%2.66M

34.09%364.37K

-50.70%275.61K

188.03%300.00K

1437.26%427.76K

381.94%271.73K

744.70%559.07K

--104.16K

--27.83K

--56.38K

--66.19K

R&D expenses

--619.69K

--651.78K

--0.00

-100.00%0.00

--0.00

-100.00%0.00

-54.04%28.55K

----

--22.44K

--50.55K

--62.12K

Depreciation, depletion, and amortization

--1.49K

--232.00

----

Other operating expenses

----

---3.00K

----

---1.00

Operating profit

-514.75%-1.84M

-522.76%-2.66M

-34.09%-364.37K

50.70%-275.61K

-188.03%-300.00K

-1437.26%-427.76K

-381.94%-271.73K

-744.70%-559.07K

---104.16K

---27.83K

---56.38K

---66.19K

Net non-operating interest income (expenses)

Non-operating interest income

48543.10%56.43K

2849.13%15.25K

-99.86%3.00

-99.46%30.00

-94.79%116.00

--517.00

--2.16K

--5.58K

--2.23K

--0.00

----

Non-operating interest expense

-80.69%6.30K

4.21%23.05K

41.34%38.03K

167.47%36.05K

303.39%32.64K

168.16%22.12K

226.16%26.91K

60.30%13.48K

--8.09K

--8.25K

--8.41K

Special income (expenses)

--12.86K

--9.52K

----

Income before tax

-435.68%-1.78M

-492.44%-2.66M

-35.73%-402.40K

45.03%-311.63K

-202.24%-332.52K

-1145.60%-449.36K

-358.71%-296.47K

-660.07%-566.97K

---110.02K

---36.08K

---64.63K

---74.59K

Income after tax

-435.68%-1.78M

-492.44%-2.66M

-35.73%-402.40K

45.03%-311.63K

-202.24%-332.52K

-1145.60%-449.36K

-358.71%-296.47K

-660.07%-566.97K

---110.02K

---36.08K

---64.63K

---74.59K

Net income from continuous operations

-435.68%-1.78M

-492.44%-2.66M

-35.73%-402.40K

45.03%-311.63K

-202.24%-332.52K

-1145.60%-449.36K

-358.71%-296.47K

-660.07%-566.97K

---110.02K

---36.08K

---64.63K

---74.59K

Net income attributable to controlling interests

-435.68%-1.78M

-492.44%-2.66M

-35.73%-402.40K

45.03%-311.63K

-202.24%-332.52K

-1145.60%-449.36K

-358.71%-296.47K

-660.07%-566.97K

---110.02K

---36.08K

---64.63K

---74.59K

Net income attributable to common shareholders

-435.68%-1.78M

-492.44%-2.66M

-35.73%-402.40K

45.03%-311.63K

-202.24%-332.52K

-1145.60%-449.36K

-358.71%-296.47K

-660.07%-566.97K

---110.02K

---36.08K

---64.63K

---74.59K

Basic earnings per share

-392.83%-0.14

-561.19%-0.26

-98.71%-0.05

45.04%-0.03

-202.21%-0.03

-1144.55%-0.04

-358.32%-0.03

-659.69%-0.05

---0.01

--0.00

---0.01

Diluted earnings per share

-392.83%-0.14

-561.19%-0.26

-98.71%-0.05

45.04%-0.03

-202.21%-0.03

-1144.55%-0.04

-358.32%-0.03

-659.69%-0.05

---0.01

--0.00

---0.01

Dividend per share

--0.00

Currency unit

USD

Audit opinions

FAQs

What is the income statement?



The income statement, also known as the profit and loss statement, shows the revenues, expenses, profits, and losses of the company over a specific accounting period.

KeyAI

